drugset / Trial / NCT00238745

Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

NCT00238745

Phase 2 Completed 375 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blind

Summary

Dose-response in Japanese patients with postmenopausal osteoporosis.

Timeline

Start
2003-08
Primary completion
Completion
2007-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg Oral
Subject Bazedoxifene Other / unclassified 40 mg Oral